Updated data on roxadustat in patients with lower-risk MDS from the open-label portion of an ongoing randomized, double-blind phase III study suggest that roxadustat reduces transfusion burden and enables transfusion independence.
In this phase II study in patients with myelofibrosis-associated anemia and RBC transfusion dependence, luspatercept meaningfully improved transfusion independence with durable responses.
Durable hematocrit and molecular responses with long-term ropeginterferon α-2b therapy for patients with polycythemia vera.
Imetelstat, a telomerase inhibitor, shows dose-dependent improvements in OS and trends in correlation with other clinical benefits in patients with JAK inhibitor–refractory, high-risk myelofibrosis.
Combination therapy with CPI-0610, a novel BET inhibitor, plus ruxolitinib shows promising activity in JAK inhibitor–naive patients with myelofibrosis in this phase II study.
Addition of pevonedistat to azacitidine significantly prolonged EFS, with a trend for extended OS and evidence of activity among patients with poor prognostic markers (eg, TP53).
In this phase III study in patients with newly diagnosed advanced myeloproliferative CMML comparing decitabine vs hydroxyurea no differences in EFS, OS, or transformation to AML were reported.
Results of this open-label phase II study show that undergoing HSCT leads to improved outcomes in older patients with high-risk MDS when compared with no HSCT.